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durationPatients and methods: In this 22 randomised phase II trial, stage III gastric cancer patients,
those with a prognosis corresponding to stage III, and macroscopically resectable stage IV
cases were randomised to two or four courses of S-1 (80 mg/m2 for 21 d with 1 week rest)/
cisplatin (60 mg/m2 at day 8) or PC (80 and 25 mg/m2, respectively, on days 1, 8, and 15 with
1 week rest) as neoadjuvant chemotherapy. The primary end-point was the 3-year overall sur-
vival (OS).
Results: Between October 2009 and July 2011, 83 patients received 2 courses of SC (nZ 21), 4
courses of SC (nZ 20), 2 courses of PC (nZ 21) and 4 courses of PC (nZ 21). The 3-year OS
was 60.9% for SC and 64.3% for PC and 64.3% for the two courses and 61.0% for the four
courses. Subset analyses demonstrated no subgroup which showed any potential survival
benefit by PC in comparison to SC or by four courses as in comparison to two courses.
Conclusions: Two courses of SC as neoadjuvant chemotherapy are recommended as a test arm
of a future phase III study for patients with locally advanced gastric cancer.
Clinical trial number: UMIN-000002595.
ª 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastric cancer remains the second leading cause of
cancer death worldwide [1]. For locally advanced dis-
ease, the standard treatment is chemotherapy and D2
gastrectomy in Asia [2], D2 plus postoperative chemo-
therapy with S-1 for 1 year in Japan [3], and D2 plus
postoperative chemotherapy with capecitabine and
oxaliplatin for around 6 months in South Korea [4].
However, the prognosis for stage III tumours is not
satisfactory, even with D2 gastrectomy and adjuvant
chemotherapy with S-1 [5]. Other approaches have been
established in the Western countries. Pre- and post-
operative chemotherapy is a standard treatment in
Europe [6e8], while pre- or postoperative chemo-
radiation with D2 is frequently selected in the United
States of America [9].
Combination chemotherapy using S-1 plus cisplatin
(SC) is a standard regimen in the treatment of metastatic
gastric cancer in Japan [10,11]. Although SC was found
to not be tolerable after surgery [12,13], it was safe and
feasible to administer SC before surgery [14e16].
Paclitaxel is another key drug that is used in the treat-
ment of metastatic disease. The combination of pacli-
taxel plus cisplatin (PC) demonstrated a high response
rate and feasibility in the treatment of metastatic disease
[17,18]. Moreover, PC achieved a high pathological
response with acceptable levels of toxicity in a neo-
adjuvant setting [19]. Both SC and PC are promising
regimens for neoadjuvant chemotherapy; however, a
suitable duration of treatment remains to be established.
Two courses have been selected in most Japanese studies
[14,20], while three courses were adopted in the MAGIC
phase III trial which confirmed its survival benefit [6]. In
contrast to neoadjuvant chemotherapy, patients receive
S-1 for 1 year or capecitabine plus oxaliplatin for6 months in the postoperative adjuvant setting after D2
gastrectomy [3,4].
Based on these previous studies, a randomised phase
II trial, COMPASS, was conducted to compare neo-
adjuvant chemotherapy with two and four courses of SC
and PC with a two-by-two factorial design for macro-
scopically resectable locally advanced gastric cancer
[21]. The primary end-point was 3-year overall survival
(OS). In our previous report, which analysed the early
outcome, the pathological response rate was found to be
similar, regardless of the regimen or course. This report
clarified the survival results of the COMPASS phase II
study. The results would be helpful for selecting a better
regimen and course for the next phase III trial to
confirm the survival benefit of neoadjuvant chemo-
therapy for gastric cancer.
2. Patients and methods
The study enrolled patients with stage III gastric cancer,
patients with a prognosis that corresponded to stage III,
and patients with macroscopically resectable stage IV
gastric cancer. The performance of thin-slice computed
tomography (CT) or multi-detector row CT and lapa-
roscopy were mandatory for the clinical staging. The T
and N criteria were precisely determined by the proto-
col. Details of the entry criteria have been reported
previously [22]. In brief, the eligibility criteria were as
follows: (i) histologically proven gastric adenocarci-
noma; (ii) T2-3/Nþ or T4aN0 in the cases of scirrhous
or junctional tumours, T2e3 with nodal metastasis to a
major branched artery, T4aNþ, T4b, para-aortic nodal
metastases, or resectable minimal peritoneal metastases
confirmed by laparoscopy; (iii) no other distant metas-
tasis; (iv) age between 20 and 80 years; (vii) an Eastern
Cooperative Oncology Group performance status of
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diation therapy for any tumours and surgery for the
present disease except bypass; and (vi) sufficient organ
functions. The participating investigators were instruc-
ted to send an eligibility criteria report to the data
center, operated by the non-profit organisation Epide-
miological and Clinical Research Information Network
(ECRIN). Eligible patients were registered and subse-
quently randomised using a centralised dynamic ran-
domisation method with the following stratification
factors: macroscopic type, oesophageal invasion, M1
stage, and creatinine clearance.
In the SC regimen, S-1 was given twice a day for a total
of 80 mg/m2 for the first 3 weeks of a 4-week cycle, and
cisplatinwas given as an intravenous infusion of 60mg/m2
on day 8 of each cycle, as described previously [22]. In the
PC regimen, paclitaxel 60 mg/m2 and cisplatin 25 mg/m2
were administered on days 1, 8, and 15 as one course,
which was repeated every 4 weeks [17]. The details of the
neoadjuvant chemotherapy treatments have been re-
ported previously. Patients proceeded to surgery
following neoadjuvant chemotherapy. Standard D2 gas-
trectomy was performed with the goal of obtaining an R0
resection [10]. After a macroscopic curative resection was
achieved, the patients were recommended to undergo
postoperative chemotherapy using S-1 for more than 6
months until 12 months, as long as the tumours did not
recur. No adjuvant treatments other than S-1 were
permitted until a recurrence developed.3. Follow-up
After surgery, the patients received a physical examina-
tion, laboratory test, and abdominal computed tomogra-
phy scan at least once every 6months until 3 years after the
accrual. Recurrence was confirmed by imaging studies,
including computed tomography, ultrasonography, lap-
aroscopy, gastrointestinal radiography, and endoscopy.
Individual patientswere followedup for at least for 5 years
after the accrual in accordance with the protocol.4. Study design and statistical methods
The present study was an open-label, randomised phase
II trial of selection design as proposed by Simon. To
lead scientifically accurate conclusion, statistical design
was conducted by our biostatistician, S.M. (Department
of Biomedical Statistics and Bioinformatics, Kyoto
University Graduate School of Medicine, Kyoto,
Japan). The primary end-point was the 3-year OS rate.
The sample size was calculated based on the hypothesis
that the 3-year OS rate was expected to be between 20
and 40% for each reference arm of the two-course
treatments and the SC regimen. When each test arm of
the four-course treatments and the PC regimen achieved
a 10% improvement against the 3-year OS rates of 20%,30%, and 40% expected in the four-course treatments or
the SC regimen, the statistical power (selection proba-
bility) was calculated to be 0.81, 0.79, and 0.78,
respectively, for a total sample size of 60 and it was
calculated to be 0.85, 0.83 and 0.82, respectively, for a
total sample size of 80. Considering these calculations,
the total number of patients to be accrued was set at
60e80. The progression of tumours was evaluated based
on the classifications of the 7th edition of the UICC-
TNM [23]. The protocol was approved by the institu-
tional review boards/ethics committees of each partici-
pating institution. This trial was registered in the
University Hospital Medical Information Network
(UMIN) center (ID: UMIN000002595).
OS curves were constructed as time-to-event plots
using the KaplaneMeier method. The time-to-event
curves were compared using log-rank tests and hazard
ratios (HRs) as estimated by Cox regression models. All
efficacy analyses were performed using intent-to-treat
populations, wherein all the randomly assigned patients
were included. All clinical data were held centrally at the
ECRIN data center and analysed using the SAS soft-
ware program (Windows version 9.3, SAS Institute Inc.,
Cary, NC, USA).5. Results
5.1. Patients
Between October 2009 and July 2011, a total of 83 pa-
tients were assigned to receive two courses of SC (SC2,
nZ 21), four courses of SC (SC4, nZ 20), two courses
of PC (PC2, nZ 21) or four courses of PC (PC4,
nZ 21). All the eligible patients met the inclusion
criteria and received neoadjuvant chemotherapy. The
characteristics of the four groups were well balanced
(Table 1). A flow diagram of the patients is presented in
Fig. 1. The R0 resection rate was 78.0% (32 of 41),
71.4% (30 of 42), 73.8% (31 of 42) and 75.6% (31 of 41)
in the SC, PC, two- and four-course groups, respec-
tively. The chemotherapy-related toxicities, surgical
morbidity, and surgical findings were reported previ-
ously. Both regimens had safe and acceptable toxicities,
regardless of whether two or four courses of treatment
were administered. The surgical morbidities between the
regimens and courses were similar. No treatment-related
deaths were observed.5.2. Prognosis
The median follow-up periods in the SC, PC, two- and
4-course arms were 38.8, 38.2, 39.2 and 37.5 months,
respectively. Fig. 2 shows the OS curves for all the
eligible patients. The HR for death in the PC arm in
comparison to the SC arm was 1.03 (95% confidence
interval [CI] 0.54e1.97) (pZ 0.921), while it was 1.13
Fig. 1. CONSORT diagram. SC2, two courses of S-1 plus cisplatin; SC4, four courses of S-1 plus cisplatin; PC2, two courses of paclitaxel
plus cisplatin; and PC4, four courses of paclitaxel plus cisplatin.
Table 1
Patient demographic and clinical characteristics.
SC2 SC4 PC2 PC4
nZ 21 nZ 20 nZ 21 n Z 21
Age (years old) Median 66.0 63.0 66.0 67.0
Range 32e79 47e76 55e80 43e77
Sex Male 14 (66.7%) 12 (60.0%) 17 (81.0%) 15 (71.4%)
Female 7 (33.3%) 8 (40.0%) 4 (19.0%) 6 (28.6%)
Performance status 0 21 (100.0%) 20 (100.0%) 20 (95.2%) 20 (95.2%)
1 0 (0.0%) 0 (0.0%) 1 (4.8%) 1 (4.8%)
Creatinine clearance (ml/min) 60 18 (85.7%) 18 (90.0%) 19 (90.5%) 18 (85.7%)
<60 3 (14.3%) 2 (10.0%) 2 (9.5%) 3 (14.3%)
Macroscopic type Scirrhous 7 (33.3%) 7 (35.0%) 6 (28.6%) 7 (33.3%)
Others 14 (66.7%) 13 (65.0%) 15 (71.4%) 14 (66.7%)
Histological type Differentiated 8 9 11 8
Un-differentiated 13 11 10 13
Oesophageal invasion Present 7 (33.3%) 5 (25.0%) 6 (28.6%) 7 (33.3%)
None 14 (66.7%) 15 (75.0%) 15 (71.4%) 14 (66.7%)
Clinical T T2 0 0 0 1
T3 1 1 2 2
T4a 17 19 17 15
T4b 3 0 2 3
Clinical N N0 1 (5.0%) 4 (20.0%) 3 (14.3%) 4 (20.0%)
N1 12 (60.0%) 8 (40.0%) 11 (52.4%) 8 (40.0%)
N2 4 (20.0%) 4 (20.0%) 5 (23.8%) 7 (35.0%)
N3 3 (15.0%) 4 (20.0%) 2 (9.5%) 1 (5.0%)
Clinical stage Stage 23 18 (85.7%) 17 (85.0%) 17 (81.0%) 18 (85.7%)
Stage 4 3 (14.3%) 3 (15.0%) 4 (19.0%) 3 (14.3%)
Minimal peritoneal metastasis None 21 (100.0%) 20 (100.0%) 19 (90.5%) 21 (100.0%)
Present 0 (0.0%) 0 (0.0%) 2 (9.5%) 0 (0.0%)
Peritoneal cytology Negative 17 (85.0%) 17 (85.0%) 19 (90.5%) 16 (80.0%)
Positive 3 (15.0%) 3 (15.0%) 2 (9.5%) 4 (20.0%)
Abbreviations: SC2, S-1/CDDP 2; SC4, S-1/CDDP 4; PC2, paclitaxel/CDDP 2; PC4, paclitaxel/CDDP 4.
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Fig. 2. Overall survival by regimen (A) and by courses (B). SC, S-1 plus cisplatin and PC, paclitaxel plus cisplatin.
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parison to the two-course arm (pZ 0.700). The 3-year
OS rate, which was the primary end-point of the pre-
sent study, was 60.9% (95% CI 44.3e73.9%) in the SC
arm and 64.3% (95% CI 47.9e76.7%) in the PC arm.
The 3-year OS rate was 64.3% (95% CI 47.9e76.7%) in
the two-course arm and 61.0% (95% CI 44.4e74.0%) in
the four-course arm. The subset analyses demonstrated
that none of the subgroups showed any potentialFig. 3. Forest plot of effects of the treatmesurvival benefit, either of PC over SC or of the four-
course treatment over the two-course treatment (Figs 3
and 4). Fig. 5 shows the OS curves in each arm. No
significant differences were found among these four
arms (pZ 0.767). The 3-year OS rate was 67% (95% CI
43e83%) in the two courses of SC and 55% (95% CI
31e73%) in the four courses of SC, while that was 62%
(95% CI 38e79%) in the two courses of PC and 67%
(95% CI 43e83%) in the four courses of PC.nt on the overall survival by regimen.
Fig. 4. Forest plot of effects of the treatment on the overall survival by courses.
T. Yoshikawa et al. / European Journal of Cancer 62 (2016) 103e111108No significant differences were found between these
two regimens (pZ 0.956) or between the two- and four-
course treatments (pZ 0.723). The site of the recur-
rence or progression in the SC and PC arms was the
peritoneum (nZ 9 and nZ 10, respectively), liverFig. 5. Overall survival in each arm. SC, S-1 plu(nZ 4 and nZ 4), lymph nodes (nZ 11 and nZ 6),
and other location (nZ 6 and nZ 8). No remarkable
differences were observed in the site of recurrence after
surgery or the site of progression during neoadjuvant
chemotherapy.s cisplatin and PC, paclitaxel plus cisplatin.
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To the best of our knowledge, the present study is the
first randomised trial to compare the duration of neo-
adjuvant chemotherapy for locally advanced gastric
cancer. The major finding of this study was that the
four-course neoadjuvant chemotherapy treatment did
not achieve a 10% improvement in 3-year OS in com-
parison to the two-course treatment. Furthermore, the
study showed a similar 3-year OS in the patients who
received SC and PC as a neoadjuvant chemotherapy
regimen. A similar tendency was confirmed in the
comparisons of four arms. The study suggested that two
courses of SC should be recommended as a candidate
test arm in a future phase III study to evaluate neo-
adjuvant chemotherapy for gastric cancer.
When conducting the present study, we hypothesised
that the OS of the patients in the four-course arm would
be better than that of the two-course arm. Theoretically,
adjuvant chemotherapy aims to eradicate micro-
metastasis existing outside the surgical field [24].
Although the optimal duration for which treatment
should be continued in order to achieve this eradication
is unclear, we had considered that two-course treatment
was too short to achieve complete eradication and that
the four-course treatment could improve the survival. In
fact, the pathological response rates of the two- and
four-course arms were very similar; however, a patho-
logical complete response was only observed in the four-
course arm, as previously reported [22]. Surprisingly, the
OS of the two- and four-course arms was very similar.
Moreover, none of the subgroups showed a tendency for
better survival in response to the four-course treatment.
These results suggested that a four-course neoadjuvant
chemotherapy treatment was not necessary to improve
the survival.
The chance to perform curative surgery may be lost
by long-term neoadjuvant chemotherapy [24], which
may worsen survival. In the present study, however, no
patient showed clinically detectable disease progression
during third or fourth courses in the four-course arm
(Fig. 1). On the other hand, disease progression was
only seen in one patient of the two-course arm, while it
was seen in four patients of the four-course arm. Two
patients of the two-course arm and four patients of the
four-course arm did not proceed to surgery. In light of
these findings, we cannot deny the possibility that the
two additional courses in the four-course arm resulted in
disease progression that was clinically undetectable.
However, the R0 resection rate was similar among the
randomised patients of the two- and four-course arms,
which suggested that the chance for curative surgery was
not lost due to the provision of long-term neoadjuvant
chemotherapy.
Another hypothesis of the present study was that PC
was associated with better survival in comparison to SC.In the present study, however, both regimens had almost
equivalent survival. Previously, two phase III trials
failed to show the survival benefit of taxanes in gastric
cancer [25,26]. In the adjuvant setting, SAMIT phase III
trial, which compared a sequential therapy of paclitaxel
followed by fluoropyrimidine and fluorppyrimidine
monotherapy for patients with serosa-positive gastric
cancer after D2 gastrectomy, could not demonstrate
superior survival in the patients who were treated with
paclitaxel [25]. In metastatic disease, the START phase
III study could not show the survival benefit of S-1
docetaxel in comparison to S-1 alone [26]. Although the
present study compared doublet regimens combining
cisplatin in a neoadjuvant setting, the results were not
surprising because both regimens had similar patho-
logical response rates. On the other hand, combination
chemotherapy of 5-FU, cisplatin, and docetaxel showed
clear survival benefit as compared with 5-FU and
cisplatin for metastatic gastric cancer. Triplet regimen
including docetaxel has a value to be evaluated in neo-
adjuvant setting in the future.
The 3-year OS was approximately 60% in the SC
reference arm and the two-course arm. This proportion
was slightly higher than the expected value of 20e40%.
The first possibility is the inclusion of patients with early
disease. However, the clinical staging had been strictly
prescribed in the protocol. In our previous report eval-
uating this method for staging, the accuracy and speci-
ficity for serosal invasion were 85.7% and 94.0%,
respectively, while the accuracy and specificity for nodal
metastasis were 81.3% and 96.8%, respectively [27]. The
very high specificity means that it is less likely that pa-
tients with early disease were enrolled. As demonstrated
in Fig. 1, most patients had T4 and nodal disease. T2
and T3 patients were only enrolled in cases of scirrhous
or junctional cancer. Thus, it is unlikely that early-stage
patients were included in the study. The second possi-
bility is a smaller number of patients with resectable
stage IV were enrolled. In fact, around 15% patients of
the patients in the present study had macroscopic stage
IV. Most physicians would be hesitant to enrol stage IV
patients in a study where patients proceed to surgery
after neoadjuvant chemotherapy. The third possibility is
that neoadjuvant chemotherapy was highly effective.
European phase III studies have clearly demonstrated
the high efficacy of perioperative chemotherapy in pa-
tients who show high compliance to neoadjuvant
chemotherapy [6,8]. The JCOG-0405 phase II study
showed that the 3-year survival rate among patients with
bulky nodal disease surrounding a major branched ar-
tery or para-aorta was more than 50%; in comparison
the 3-year survival rate in the historical controls was
only 10% [28].
In conclusion, the 3-year OS was similar regardless of
whether the patients received two or four courses of SC
or PC as a neoadjuvant chemotherapy. The study
T. Yoshikawa et al. / European Journal of Cancer 62 (2016) 103e111110suggested that two courses of SC should be recom-
mended as a test arm candidate for a future phase III
study to evaluate the effectiveness of neoadjuvant
chemotherapy for gastric cancer.
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